Zealand CEO: cancelled agreement is positive news
Swiss drug group Helsinn has returned the rights to a Zealand-developed drug to the Danish company and thus, cancelled an almost nine year old license agreement. However, Zealand’s CEO Britt Meelby Jensen is far from pessimistic.
BY MARTIN HAVTORN PETERSEN
In the beginning of this week, the Danish biotech company Zealand Pharma got back the rights to its experimental GLP-2 analogue elsiglutide from its – now former – Swiss partner Helsinn. Though falling into disfavor usually is disappointing, Zealand’s CEO Britt Meelby Jensen does not see the finished partnership as bad news for her company.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Partner gives up rights to potential Zealand drug
For abonnenter
Zealand initiates obesity study together with Boehringer
For abonnenter
